Asthma

Atrial Fibrillation

Autoimmune Diseases

Biologics

Biosimilars

Blood Cancer

Breast Cancer

COVID-19

Cardiovascular Diseases

Depression

Dermatology

Diabetes

Digital Health

Drug Coverage

Duchenne Muscular Dystrophy

Eyecare

Friedreich Ataxia

Gene Therapy

Graft Versus Host Disease

Heart Failure

Hemophilia

Hypertrophic Cardiomyopathy (HCM)

Leukemia and Lymphoma

Liver Disease

Lung Cancer

Mental Health

Multiple Sclerosis

NSCLC

Neonatal Care

Nephrology

Obstetrics-Gynecology & Women's Health

Oncology

Opioids

PTSD

Pain

Pediatrics

Plaque Psoriasis

Population Health

Post-Acute Care

Prescription Digital Therapeutics

Pulmonary Arterial Hypertension

Reproductive Health

Respiratory Conditions

Safety & Recalls

Skin Cancer

Sleep Disorders

Solid Tumors

Spinal Muscular Atrophy

Substance Use Disorder

The Improving Patient Access Podcast

Type I Diabetes

Type II Inflammation

Ulcerative Colitis

Urology

Urothelial Carcinoma

Vaccines

Women's Health

News

Media

Between the Lines

Expert Interviews

K-Cast

Medical World News

Podcasts

Population Health Perspectives

Conferences

Partners

Publications

All Publications

MHE Publication

Formulary Watch Supplements

Formulary Watch Spotlights

Supplements And Featured Publications

Events

2024 PBMI Annual National Conference

PBMI MAP

Virtual Events

CME/CE

Resources

Emerging Leaders

Interactive Tools

PBM Leaders

PBMI Innovators

Subscribe

Articles

Researchers of a new JAMA study said that without further participation in accountable care organizations, including the ACO REACH model, the program is unlikely to meet its goal of reducing health disparities.

ACO REACH Misses Targett In Serving High-Risk Groups

CVS Health released a statement shortly after HB1150 was signed in Arkansas, prohibiting pharmacy benefit managers from owning pharmacies.

CVS to Close More Than 20 Pharmacies in Arkansas

Videos

In a recent conversation with Managed Healthcare Executive, Geoffrey Rutledge, M.D., of HealthTap, warned that the narrative around GLP-1 drugs is often oversimplified—and potentially harmful.

Why GLP-1 Drugs Alone Aren’t Enough for Lasting Weight Loss

Peter Wehrwein has been the lead editor of Managed Healthcare Executive since February 2020.

On lobbying, hospitals, PBM reform and 340B

A Conversation With Shawn Gremminger, M.P.P., the Newest Member of the MHE Editorial Advisory Board

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for value-driven solutions.

About Us

Advertise

Editorial

Contact Us

Terms and Conditions

Privacy

Do Not Sell My Personal Information

Managed Healthcare Executive

Facebook

LinkedIn

Resource Centers

Eye Care

Spotlight

Dermatology Conference Coverage

AMCP Annual

K-Cast: Optimizing Narcolepsy Care

Business

Business Strategy

Chronic Disease

Consumers

Drug Costs

Drug Pipeline

Formulary

Health Management

Health/Disease Strategy

Hospitals & Providers

Industry Analysis

Pharmacy

Politics and Policy

Practice Management

Reimbursement

Technology

1rem

View

Secondary Progressive Multiple Sclerosis: Patient Impact and Coverage Implications for New Therapies

Secondary Progressive Multiple Sclerosis: Patient Impact and Coverage Implications for New Therapies EP8

Challenges Regarding Coverage for New SPMS Therapies

Evolving Treatment Strategies and Coverage Implications

The Clinical and Economic Burden of SPMS

Fred Lublin, MD, says it's possible health professionals can develop some biomarkers and find some differences in advanced MRI metrics in finding Secondary Progressive Multiple Sclerosis.



Determining SPMS as Biological Instead of Classification

Thomas P. Leist, MD, PhD, discusses secondary progressive MS, more specifically how very early control of the disease gives the patient the best chance for long term stability and gives the patient, the best chance of not entering the secondary state.


Tackling Secondary Progressive Multiple Sclerosis Early on Benefits Patients in a Number of Ways

Thomas P. Leist, MD, PhD, says doctors working with patients diagnosed with SPMS don't necessarily have prognostic biomarkers to detect SPMS. The best prognostic biomarkers they have currently are MRI and potentially neurofilament light. He adds their techniques need to improve in order to harness the full benefit of potentially individualizing care to the most optimal fashion in a given patient.

Biomarkers Used to Detect Secondary Progressive MS Needs Improvement for the Care of Patients

Defining active SPMS

Thomas P. Leist, MD, PhD, explains that there is no such thing as "one size fits all" for patients with SPMS. Patients can be impacted differently based on how they present themselves and how they behave.


How Patients Present SPMS, How to Act on it

Fred Lublin, MD, says a new labeling indication of Secondary Progressive Multiple Sclerosis broadens whom you can treat. He adds this will be very helpful to patients because it will treat groups that are progressing slowly without agents of activity.


A Labeling Indication of SPMS Can Treat More Patients

Thomas P. Leist, MD, PhD, says one of the things secondary progressive multiple sclerosis professionals struggle with is making the most effective treatment available to patients, very early on, most likely due to financial reasons.

The Struggle of Making an Effective SPMS Treatment Early on

Unmet Needs for All and Most Vulnerable Secondary Progressive MS Patients

Population Health Perspectives is a recurring content series published on MHE and Formulary Watch through print, digital and video avenues. The series focuses on updates around new real-world evidence/data and trends that stand to impact treatment guidelines, access decisions, and patient experience.